High-dose Intravenous Vitamin C for the Treatment of Severe Acute Pancreatitis
- Conditions
- Severe Acute Pancreatitis
- Interventions
- Drug: Vitamin C (Ascorbic Acid)Drug: Saline (NaCl 0,9 %)
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 388
- Registration Number
- NCT06897384
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai, Shanghai, China
Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma
- Conditions
- Epstein-Barr Virus Associated Lymphoma
- Interventions
- Drug: EBV mRNA vaccine (WGc-043)
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06788600
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Efficacy and Safety of tACS for Depression: a Multicenter RCT Study
- Conditions
- Depression Disorders
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT06891326
- Locations
- 🇨🇳
Ruijin Hospital affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
- Conditions
- Gastric AdenocarcinomaGEJ AdenocarcinomaFirst-line TherapyMaintenance TherapyFruquintinibPD-1
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT06888037
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Flow Index: a New Method for Assessing Respiratory Drive in Critically Ill Patients Based on Electrical Impedance Tomography
- Conditions
- Respiratory DriveAcute Respiratory Failure
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06876792
- Locations
- 🇨🇳
197 Ruijin Er Road, Huangpu District, Shanghai, Shanghai, China
🇨🇳Department of Critical Care Medicine，Ruijin Hospital，Shanghai Jiao Tong University School of Medicine，Shanghai，China., Shanghai, China
The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06876701
- Locations
- 🇨🇳
Shanghai Zhaxin integrated hospital of traditional Chinese and Western Medicine, Shanghai, China
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
- Conditions
- CNS Lymphoma
- Interventions
- Drug: Relma-cel Followed by Tislelizumab
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06876688
- Locations
- 🇨🇳
Beljing Tiantan Hospital, Capttal Medical, University, Beijing, China
🇨🇳Xuanwu Hospital Capital Medical University, Beijing, China
🇨🇳Sun Yat-Sen University Cancer Center, Guangzhou, China
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
- Conditions
- T-NK Cell Lymphoma
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06863441
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School, Shanghai, Shanghai, Shanghai, China
A Study on the Changes and Prognosis of Intestinal Microbiota and Function in Infants With Food Allergies
- Conditions
- HealthChildrenGut Microbiota
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06854536
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors
- Conditions
- Precise Design of Cell Therapy for Relapsed and Refractory Hematological TumorsHematologic Disease
- Interventions
- Drug: Cellular Therapy
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06849921
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China